Lung Cancer
Volume 66, Issue 3 , Pages 292-297 , December 2009

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma

  • Jaya Sangodkar

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Analisa DiFeo

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Lauren Feld

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Romina Bromberg

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Rachel Schwartz

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Fei Huang

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Esteban A. Terzo

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Aisha Choudhri

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • ,
  • Goutham Narla

      Affiliations

    • Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, United States
    • Department of Medicine, Mount Sinai School of Medicine, New York, NY, United States
    • Corresponding Author InformationCorresponding author at: Mount Sinai School of Medicine, 1425 Madison Ave, Room 14-20, New York, NY 10029, United States. Tel.: +1 212 659 6732.

Received 24 October 2008 ,Revised 12 February 2009 ,Accepted 19 February 2009.

References 

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10–30
  2. Strauss GM. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances. Hematol Oncol Clin North Am. 2005;19:263–281
  3. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non small-cell lung cancer. J Clin Oncol. 2005;23:3257–3269
  4. Olaussen KA, Mountzios G, Soria JC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm. 2007;13:284–289
  5. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol. 2006;6:350–354
  6. Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 2001;294:2563–2566
  7. Reeves HL, Narla G, Ogunbiyi O, et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 2004;126:1090–1103
  8. Kremer-Tal S, Reeves HL, Narla G, et al. Frequent inactivation of the tumor suppressor kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology. 2004;40:1047–1052
  9. Cho YG, Kim CJ, Park CH, et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene. 2005;24:4588–4590
  10. DiFeo A, Narla G, Hirshfeld J, et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res. 2006;12:3730–3739
  11. Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Cancer. 2003;105:625–629
  12. Kettunen E, Anttila S, Seppanen JK, et al. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004;149:98–106
  13. Ito G, Uchiyama M, Kondo M, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 2004;64:3838–3843
  14. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002;2:485–495
  15. Hirasawa Y, Arai M, Imazeki F, et al. Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology. 2006;71:77–85
  16. Narla G, Difeo A, Reeves HL, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 2005;65:1213–1222
  17. Narla G, DiFeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 2005;65:5761–5768
  18. Beer DG, Kardia SLR, Huang CC, et al. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816–824
  19. DiFeo A, Feld L, Rodriguez E, et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 2008;68:965–970
  20. DiFeo A, Narla G, Huang F, et al. Inhibition of KLF6-SV1 increases ovarian cancer survival through the regulation of NOXA, Cancer Res, in press.
  21. Narla G, DiFeo A, Fernandez Y, et al. KLF6-SV1 is a key regulator of metastasis and survival in prostate cancer. J Clin Invest. 2008;118:2711–2721

PII: S0169-5002(09)00112-3

doi: 10.1016/j.lungcan.2009.02.014

Lung Cancer
Volume 66, Issue 3 , Pages 292-297 , December 2009

Article Tools

* Image Usage & Resolution